The cooperation will involve accelerating the delivery of Pfizer's new drugs to patients, according to a statement from Pfizer
PHOTO
Pfizer said on Thursday it has signed a strategic cooperation agreement with China's Sinopharm Group, and plans to seek approval to market 12 innovative drugs in China through 2025.
Sinopharm's president Liu Yong said during the signing event in Shanghai on Wednesday that the cooperation will involve accelerating the delivery of Pfizer's new drugs to patients, according to a statement from Pfizer.
(Reporting by Brenda Goh, Meg Shen and Ethan Wang; Editing by Bernadette Baum)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
© ZAWYA 2024
